Sponsors (26)
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
The bill substantially expands access to and confidentiality for HIV prevention—reducing out‑of‑pocket costs and addressing disparities—while imposing new federal spending, administrative burdens, potential premium increases, and legal/implementation risks that may be unevenly distributed across states and providers.
Private insurance enrollees, Medicaid/CHIP recipients, Medicare beneficiaries, veterans, TRICARE users, and federal employees will get FDA‑approved HIV prevention drugs and required monitoring with no cost‑sharing and without prior authorization, speeding and lowering-cost access to prevention.
Uninsured, underinsured, and over‑represented communities (including racial/ethnic minorities, LGBTQ people, and people in high‑need areas) will gain expanded access through new state and community grants, PrEP navigators, adherence support, and strengthened clinic capacity at FQHCs, rural clinics, and IHS facilities.
People taking PrEP will not be denied coverage or charged higher premiums for life, disability, or long‑term care insurance solely because they use HIV‑prevention medication, protecting access to coverage and reducing stigma-driven insurance barriers.
Taxpayers and federal/state budgets will face increased spending to fund grants, outreach campaigns, and expanded coverage (multiple appropriations/"such sums as necessary" authorizations through FY2026–FY2030), raising fiscal costs.
Health insurance enrollees and middle‑class families may see higher premiums or plan costs over time because insurers and public programs must cover drugs and monitoring without cost‑sharing and cannot use prior authorization or certain underwriting practices.
Insurers, employers, plan administrators, providers, and grantees will face substantial administrative and compliance burdens (data collection/submission for years, system updates for billing/HIPAA, grant reporting and applications), raising costs and operational strain.
Based on analysis of 20 sections of legislative text.
Requires most private and federal plans to cover FDA‑approved HIV prevention drugs and related services with no cost‑sharing or routine prior authorization; funds education and grants; adds privacy and nondiscrimination protections.
Requires most private group and individual health plans, FEHB plans, and certain federal programs to cover FDA‑approved HIV prevention drugs (PrEP/PEP) and related clinical services with no cost‑sharing and restricts prior authorization for those services. Directs HHS (with CDC and partners) to run public and provider education campaigns, to monitor and enforce plan compliance, to create a grant program for PrEP/PEP delivery, to amend HIPAA to protect patient confidentiality for preventive services, and to bar life, disability, and long‑term care insurers from discriminating based on use of HIV prevention medication. The bill also creates a private right of action for violations and requires insurer/plan reporting and periodic reports to Congress.